- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01700972
Feasibility and Diagnostic Accuracy of Myocardial Perfusion Imaging Using Early Imaging Protocol
Feasibility and Diagnostic Accuracy of Myocardial SPECT Using Early Imaging Protocol: A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The current MPI protocol entails imaging within 30-45 minutes after radiotracer injection (W30 imaging), for both the rest and stress part. This delay between the radiotracer injection and imaging is intended to limit the nonspecific liver and gut radioactivity to the heart and allows an optimal imaging of the heart. A recent publication however indicates that an early imaging within 10 minutes after radiotracer injection (W10 imaging) appears feasible and may be as good as W30 imaging.
Encouraged by the recent data, we think that a waiting time of 10 minutes is feasible while preserving the image quality; thus, we would like to assess the feasibility and accuracy of W10 imaging compared with W30 imaging in this study. The main purpose of this study is to obtain imaging information on the use of early imaging (W10). The feasibility of W10 imaging will be assessed visually using a 3-point scale as well as semiquantitatively using region-of-interest measurements. The accuracy of W10 imaging will be determined by comparing the findings of W10 with those of coronary angiography, which will be obtained within 30 days of the MPI and serve as reference standard. The tolerability of W10 will be assessed using 3-point scale Questionnaires.
This study will determine if early MPI imaging within 10 minutes works as well as imaging after 30-45 minutes waiting and its role in the diagnosis of coronary artery disease. The major advantages of this new imaging procedure include the shortening of the procedure time, the reduction of patient discomfort and improvement of patient care.
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Saint Louis University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women ≥18 years of age of any race /ethnicity
- Patient has undergone or is being scheduled for a clinically indicated cardiac catheterization with or without angioplasty
- Patient may have suffered myocardial infarction more than 3 days before MPI
- Patient may have undergone percutaneous transluminal coronary angioplasty (PTCA) or coronary stent placement more than 3 days prior to MPI
- Interval between T99m-MPI and cardiac catheterization is within 30 days
- Females are not pregnant and lactating
- Provide signed Informed Consent prior to undergoing the study procedures
Exclusion Criteria:
- Patients less than 18 years of age
- Female patient is pregnant or nursing
- Patient has been involved in any other investigative, radioactive research procedure within 7 days and during the study participation period
- History of 2nd or 3rd degree AV-block, or sinus node dysfunction unless the patients have a functioning artificial pacemaker
- Myocardial infarction within 3 days before MPI
- Percutaneous transluminal coronary angioplasty (PTCA) or stent placement within 3 days prior to MPI
- Current ventricular tachycardia, atrial fibrillation, atrial tachycardia, or atrial flutter
- Current history of exacerbated COPD or asthma
- Known hypersensitivity or contraindication to regadenoson or aminophylline
- Use of caffeinated substance, dipyridamole-containing medication, aminophylline, or xanthines containing medication (e.g. theophylline) within the 12 hours prior to Lexiscan administration.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Imaging at 10-minute vs. 30-45-minutes
The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging.
The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
|
The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging.
The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility and accuracy of early imaging at 10 minutes (W10) vs. standard imaging at 30-45 minute after radiotracer injection
Time Frame: 30 days
|
The feasibility of W10 imaging will be assessed visually using a 3-point scale as well as semiquantitatively using region-of-interest measurements.
The accuracy of W10 imaging will be determined by comparing the findings of W10 with those of coronary angiography, which will be obtained within 30 days of the MPI and serve as reference standard.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tolerability of early imaging at 10 minutes (W10)
Time Frame: Two hours
|
The tolerability of W10 will be assessed using 3-point scale Questionnaires.
|
Two hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Nghi Nguyen, MD, PhD, St. Louis University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- REGA-12B03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Myocardial perfusion imaging
-
National Heart Centre SingaporeNational Medical Research Council (NMRC), SingaporeRecruitingCoronary Artery Disease | Diabetes MellitusSingapore
-
Aspire FoundationBlue Cross Blue Shield; Saint Luke's Cardiovascular Consultants; Cardiovascular... and other collaboratorsCompletedCoronary Artery DiseaseUnited States
-
Karolinska InstitutetActive, not recruitingMyocardial IschemiaSweden
-
Ottawa Heart Institute Research CorporationCompletedCoronary Artery DiseaseCanada
-
University Hospital Birmingham NHS Foundation TrustCompletedLiver Failure | Myocardial Perfusion Imaging
-
Medhat Osman MDAstellas Pharma US, Inc.WithdrawnCoronary Artery Disease | Atherosclerosis
-
Peter HovindNot yet recruitingMyocardial Blood FlowDenmark
-
Hospices Civils de LyonTerminatedCoronary Heart DiseaseFrance
-
Far Eastern Memorial HospitalUnknownHypertrophic Cardiomyopathy | Myocardial Perfusion ImagingTaiwan
-
University of EdinburghCompleted